Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) saw a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 663,500 shares, a drop of 20.5% from the June 30th total of 834,700 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 402,300 shares, the short-interest ratio is presently 1.6 days.
In related news, major shareholder John K. Jr. Scott purchased 4,000,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was bought at an average price of $0.75 per share, for a total transaction of $3,000,000.00. Following the purchase, the insider now directly owns 5,113,078 shares in the company, valued at approximately $3,834,808.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have bought 4,005,350 shares of company stock valued at $3,007,611.
A hedge fund recently raised its stake in Navidea Biopharmaceuticals stock. Virtu Financial LLC increased its holdings in Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) by 94.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 186,972 shares of the biopharmaceutical company’s stock after buying an additional 90,647 shares during the period. Virtu Financial LLC owned 0.09% of Navidea Biopharmaceuticals worth $26,000 as of its most recent SEC filing.
NAVB opened at $0.51 on Thursday. Navidea Biopharmaceuticals has a 12 month low of $0.49 and a 12 month high of $7.40.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.26 million for the quarter.
About Navidea Biopharmaceuticals
Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.